Onkolojik Tedaviye Bağlı Periferik Vasküler Hastalıklar ve İnmede Tanı ve Tedavi Yaklaşımları

Al-Zahrani H, Gupta V, Minden MD, et al. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003;44:471–475.

Staff S, Lagerstedt E, Seppanen J, et al. Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer. Acta Obstet Gynecol Scand. 2011;90:1296–1297.

Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288–292.

Kuhar CG, Mesti T, Zakotnik B. Digital ischemic events related to gemcitabine: Report of two cases and a systematic review. Radiol Oncol. 2010;44:257–261.

Zeidman A, Dicker D, Mittelman M. Interferon-induced vasospasm in chronic myeloid leukaemia. Acta Haematol. 1998;100:94–96.

Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in cml. Am J Hematol. 2011;86:533–539.

Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337–340.

Levato L, Cantaffa R, Kropp MG, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: A single institution study. Eur J Haematol. 2013;90:531–532.

Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Aphase 2 trial of ponatinib in philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.

Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–2088.

Nicolini FE, Gagnieu M-C, Heiblig M, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood. 2013;122:4020.

Coon EA, Zalewski NL, Hoffman EM, et al. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol. 2013;88:534–535.

Jager NG, Stuurman FE, Baars JW, et al. Cerebrovascular events during nilotinib treatment. Neth J Med. 2014;72:113–114.

Ranpura V, Hapani S, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol. 2010;49:287–297.

Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231.

Ropert S, Vignaux O, Mir O, et al. Vegf pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs. 2011;29:1497–1499.

Fernandes DD, Louzada ML, Souza CA, et al. Acute aortic thrombosis in patients receiving cisplatin-based chemotherapy. Curr Oncol. 2011;18:e97–e100.

Grenader T, Shavit L, Ospovat I, et al. Aortic occlusion in patients treated with cisplatin-based chemotherapy. Mt Sinai J Med. 2006;73:810–812.

Breccia M, Colafigli G, Molica M, et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90:E100–101.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24; Eur Heart J. 2016;37(36):2768-2801.

Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol. 2010;30:311– 319.

El Amrani M, Heinzlef O, Debroucker T, et al. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology. 1998;51:899–901.

Serrano-Castro PJ, Guardado-Santervas P, Olivares-Romero J. Ischemic stroke following cisplatin and 5-fluorouracil therapy: A transcranial doppler study. Eur Neurol. 2000;44:63–64.

Meattini I, Scotti V, Pescini F, et al. Ischemic stroke during cisplatin-based chemotherapy for testicular germ cell tumor: Case report and review of the literature. J Chemother. 2010;22:134–136.

Kuan AS, Teng CJ, Wu HH, et al. Risk of ischemic stroke in patients with ovarian cancer: A nationwide population-based study. BMC Med. 2014;12:53.

Fraum TJ, Kreisl TN, Sul J, et al. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011;105:281–289.

Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (cns) hemorrhage. Cancer Chemother Pharmacol. 2013;71:1561–1565.

Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239.

Mantia-Smaldone GM, Bagley LJ, Kasner SE, et al. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Gynecol Oncol Case Rep. 2013;5:37–39.

Saif MW, Isufi I, Peccerillo J, et al. Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. Gastroenterol Res Pract. 2011;2011:616080.

Singer S, Grommes C, Reiner AS, et al. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist. 2015;20:806–811.

Foerster R, Welzel T, Debus J, et al. Posterior reversible leukoencephalopathy syndrome associated with pazopanib. Case Rep Oncol. 2013;6:204–208.